Hematopoietic Stem Cell TransplantationTransplantation, HomologousUnrelated DonorsTransplantation ConditioningGraft vs Host DiseaseTissue DonorsHematologic NeoplasmsBone Marrow TransplantationHistocompatibility TestingTransplantation, AutologousMyeloablative AgonistsHistocompatibilityStem Cell TransplantationWhole-Body IrradiationTransplantation ChimeraCord Blood Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationBone MarrowGraft SurvivalTreatment OutcomeBone Marrow CellsVidarabineLeukemiaHLA AntigensLiver TransplantationRecurrenceHematopoietic Stem CellsSiblingsRetrospective StudiesBusulfanLiving DonorsSurvival AnalysisImmunosuppressive AgentsDonor SelectionLeukemia, Myeloid, AcuteGraft vs Tumor EffectDisease-Free SurvivalKidney TransplantationSurvival RateMyelodysplastic SyndromesGraft RejectionRemission InductionChimerismAnemia, AplasticGraft vs Leukemia EffectHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ImmunologyAntilymphocyte SerumTime FactorsCell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAcute DiseaseDirected Tissue DonationHematopoiesisBlood DonorsCyclosporineFollow-Up StudiesMycophenolic AcidAllograftsCombined Modality TherapyTransplantationMultiple MyelomaLymphocyte DepletionImmunosuppressionHeart TransplantationLymphocyte TransfusionCyclophosphamideFetal BloodT-LymphocytesRisk FactorsLung TransplantationSurvivorsLymphoma, Non-HodgkinCytomegalovirus InfectionsHepatic Veno-Occlusive DiseaseAntigens, CD34TacrolimusSevere Combined ImmunodeficiencyHematopoietic Stem Cell MobilizationMinor Histocompatibility AntigensInfectionSalvage TherapyTransplantation, IsogeneicPrognosisOrgan TransplantationMucopolysaccharidosis IChronic DiseaseReceptors, KIRLeukemia, MyeloidMice, Inbred C57BLAntineoplastic Combined Chemotherapy ProtocolsMelphalanFanconi AnemiaIncidenceIslets of Langerhans TransplantationCohort StudiesMesenchymal Stem Cell TransplantationLymphomaTissue and Organ Procurement